Literature DB >> 24637887

Vaccines against Clostridium difficile.

Rosanna Leuzzi1, Roberto Adamo1, Maria Scarselli1.   

Abstract

Clostridium difficile infection (CDI) is recognized as a major cause of nosocomial diseases ranging from antibiotic related diarrhea to fulminant colitis. Emergence during the last 2 decades of C. difficile strains associated with high incidence, severity and lethal outcomes has increased the challenges for CDI treatment. A limited number of drugs have proven to be effective against CDI and concerns about antibiotic resistance as well as recurring disease solicited the search for novel therapeutic strategies. Active vaccination provides the attractive opportunity to prevent CDI, and intense research in recent years led to development of experimental vaccines, 3 of which are currently under clinical evaluation. This review summarizes recent achievements and remaining challenges in the field of C. difficile vaccines, and discusses future perspectives in view of newly-identified candidate antigens.

Entities:  

Keywords:  CDI; Clostridium difficile; vaccine

Mesh:

Substances:

Year:  2014        PMID: 24637887      PMCID: PMC5396221          DOI: 10.4161/hv.28428

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  151 in total

1.  Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.

Authors:  Nicole J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

3.  Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.

Authors:  Chandrabali Ghose; Anuj Kalsy; Alaullah Sheikh; Julianne Rollenhagen; Manohar John; John Young; Sean M Rollins; Firdausi Qadri; Stephen B Calderwood; Ciaran P Kelly; Edward T Ryan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

4.  Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains.

Authors:  Frédéric Barbut; Dominique Decré; Valérie Lalande; Béatrice Burghoffer; Latifa Noussair; Anne Gigandon; Florence Espinasse; Laurent Raskine; Jérome Robert; Alain Mangeol; Catherine Branger; Jean-Claude Petit
Journal:  J Med Microbiol       Date:  2005-02       Impact factor: 2.472

Review 5.  Clostridium difficile toxins: more than mere inhibitors of Rho proteins.

Authors:  Harald Genth; Stefanie C Dreger; Johannes Huelsenbeck; Ingo Just
Journal:  Int J Biochem Cell Biol       Date:  2008-01-05       Impact factor: 5.085

6.  Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008.

Authors:  E J Kuijper; F Barbut; J S Brazier; N Kleinkauf; T Eckmanns; M L Lambert; D Drudy; F Fitzpatrick; C Wiuff; D J Brown; J E Coia; H Pituch; P Reichert; J Even; J Mossong; A F Widmer; K E Olsen; F Allerberger; D W Notermans; M Delmée; B Coignard; M Wilcox; B Patel; R Frei; E Nagy; E Bouza; M Marin; T Akerlund; A Virolainen-Julkunen; O Lyytikäinen; S Kotila; A Ingebretsen; B Smyth; P Rooney; I R Poxton; D L Monnet
Journal:  Euro Surveill       Date:  2008-07-31

7.  Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins.

Authors:  Claire Janoir; Séverine Péchiné; Charlotte Grosdidier; Anne Collignon
Journal:  J Bacteriol       Date:  2007-08-10       Impact factor: 3.490

8.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Authors:  David F Gardiner; Talia Rosenberg; Jerry Zaharatos; David Franco; David D Ho
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

9.  Binary toxin and death after Clostridium difficile infection.

Authors:  Sabrina Bacci; Kåre Mølbak; Marianne K Kjeldsen; Katharina E P Olsen
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

10.  Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.

Authors:  Ignazio Castagliuolo; Marina Sardina; Paola Brun; Chiara DeRos; Cristina Mastrotto; Laura Lovato; Giorgio Palù
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more
  28 in total

Review 1.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

2.  Current advances and challenges in the development of Acinetobacter vaccines.

Authors:  Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis.

Authors:  Ola H Negm; Mohamed R Hamed; Elizabeth M Dilnot; Clifford C Shone; Izabela Marszalowska; Mark Lynch; Christine E Loscher; Laura J Edwards; Patrick J Tighe; Mark H Wilcox; Tanya M Monaghan
Journal:  Clin Vaccine Immunol       Date:  2015-07-15

Review 4.  Adult vaccination.

Authors:  Kena A Swanson; H Josef Schmitt; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

5.  Optimal control of vaccination rate in an epidemiological model of Clostridium difficile transmission.

Authors:  Brittany Stephenson; Cristina Lanzas; Suzanne Lenhart; Judy Day
Journal:  J Math Biol       Date:  2017-05-08       Impact factor: 2.259

6.  A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection.

Authors:  Ola H Negm; Mohamed Hamed; Tanya M Monaghan
Journal:  J Vis Exp       Date:  2018-06-15       Impact factor: 1.355

7.  Vaccines for Healthcare-associated Infections: Promise and Challenge.

Authors:  Jane M Knisely; Baoying Liu; Ryan T Ranallo; Lanling Zou
Journal:  Clin Infect Dis       Date:  2016-05-20       Impact factor: 9.079

Review 8.  Clostridium difficile Infection.

Authors:  Jae Hyun Shin; Esteban Chaves-Olarte; Cirle A Warren
Journal:  Microbiol Spectr       Date:  2016-06

9.  Adaptive immune constraints on C. difficile vaccination.

Authors:  Mark L Lang; Binu Shrestha
Journal:  Expert Rev Vaccines       Date:  2017-09-19       Impact factor: 5.217

10.  Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials.

Authors:  James Baggs; Kimberly Yousey-Hindes; Elizabeth Dodds Ashley; James Meek; Ghinwa Dumyati; Jessica Cohen; Matthew E Wise; L Clifford McDonald; Fernanda C Lessa
Journal:  Vaccine       Date:  2015-10-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.